The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making-Reference-Cited by-同舟云学术

The Combination of Exposure-Response and Case-Control Analyses in Regulatory Decision Making

Published:2013-01-24 Issue:2 Volume:53 Page:160-166
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:J Clin Pharmacol

Author:

Yang Jun¹,Zhao Hong¹,Garnett Christine¹,Rahman Atiqur¹,Gobburu Jogarao V.¹,Pierce William²,Schechter Genevieve²,Summers Jeffery²,Keegan Patricia²,Booth Brian¹,Wang Yaning¹

Affiliation:

1. Office of Clinical Pharmacology, Office of Translational Sciences; Food and Drug Administration; Silver Spring, MD; USA

2. Office of Oncology Drug Products, Office of New Drugs; Food and Drug Administration; Silver Spring, MD; USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference15 articles.

1. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis;Roy;J Clin Pharmacol,2007

2. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients;Mould;Clin Pharmacol Ther,2005

3. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia;Friberg;Clin Pharmacol Ther,2009

4. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20;Dayde;Blood,2009

5. Analysis of ixabepilone exposure-response for neutropenia in patients with metastatic breast cancer;Roy;J Clin Oncol,2008

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics of trastuzumab and its efficacy and safety in HER2-positive cancer patients;Cancer Chemotherapy and Pharmacology;2024-08-23

2. Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL;JTO Clinical and Research Reports;2024-07

3. Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non‐small‐Cell Lung Cancer in Patients Aged 75 Years and Older;Clinical Pharmacology & Therapeutics;2024-06-17

4. Monoclonal Antibodies: From Structure to Therapeutic Application;Pharmaceutical Biotechnology;2024

5. UGT1A1 genotype‐guided irinotecan dosing during neoadjuvant chemoradiotherapy for locally advanced rectal cancer: A prospective analysis of SN‐38 concentration;International Journal of Cancer;2023-12-29